REGENXBIO Inc. revenue by segment RGNX

Annual Quarterly

REGENXBIO Inc. splits its revenue into 8 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Nippon Shinyaku Services at $3.3 million, 36% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	154	9	108	6	30	30	21	89	21
Abb Vie Development Milestone	—	—	100 share 92.6%	—	—	—	—	—	—
License And Service	—	—	—	5 -94.2% share 79.6%	27 +28.0% share 89.5%	24 share 79.4%	18 share 86.5%	87 share 97.8%	21 share 100.0%
Nippon Shinyaku Services	—	3 -44.2% share 36.1%	4 +36.8% share 3.4%	1 -43.0% share 15.8%	1 share 4.6%	6 share 20.0%	3 share 12.7%	2 share 2.0%	—
Nippon Shinyaku Licenses	—	—	—	—	3 share 9.6%	—	—	70 share 78.6%	—
Itvisma Royalties	—	3 share 30.7%	2 share 1.9%	0 share 4.7%	—	—	—	—	—
Zolgensma Royalties	—	2 -89.7% share 26.5%	2 -90.5% share 1.6%	5 -72.1% share 74.3%	24 +13.9% share 77.6%	24 share 79.3%	18 share 86.3%	17 share 19.1%	21 share 97.4%
Other Service Revenue	—	1 +210.7% share 6.6%	0 +163.2% share 0.4%	0 +54.5% share 4.6%	2 +320.9% share 5.9%	0 share 0.7%	0 share 0.8%	0 share 0.2%	0 share 2.0%
Services	—	—	—	—	—	—	—	—	0 share 2.0%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: RGNX (Nasdaq)
Fiscal year ends: December 31
Headquarters: Rockville, MD
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1590877
Former names: ReGenX Biosciences, LLC (until Nov 7, 2013)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.